Blueprint Medicines (BPMC)

Kristin Hodous Investor Relations
Jeff Albers Chief Executive Officer
Andy Boral Chief Medical Officer
Mike Landsittel Vice President, Finance
Marion Dorsch Chief Scientific Officer
Terence Flynn Goldman Sachs
Eric Schmidt Cowen and Company
Sarah Frank Raymond James
Dane Leone BTIG
Carmen Augustine Jefferies
Mike King JMP Securities
Arlinda Lee Canaccord
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.

Good day, ladies and gentlemen, and welcome to the Q3 2017 Blueprint Medicines Corp. Earnings Conference Call. [Operator Instructions] As a reminder, this conference maybe recorded. I would like to introduce your host for today's conference, Kristin Hodous.

You may begin.

Kristin Hodous

operator. you, Thank Good morning. Blueprint XXXX third conference financial of and to call. Hodous welcome Medicines and Medicines Kristin quarter Blueprint is This operating results topics This which discuss a issued that the today. morning to we press plan we outlines release release our site of at Investors Web is available The the section on www.blueprintmedicines.com. discuss Today call, will Chief quarter third Executive Albers, our Medicines’ XXXX on Officer, Jeff Blueprint business highlights. Scientific Officer on portfolio. update will our an Chief provide our Dorsch, Marion research Vice President financial of Finance, our review quarter Landsittel, will results. third Mike And

call for Chief the questions. Dr. also We the our open will will your Andy Boral, for Medical on then Q&A. is Officer, be call and available

including differ we uncertainties, we from other implied or any with Form would forth make Before include of those most recent factors, of like Quarterly Factors forward-looking the statements the various conference by and the other a with result section statements this on those may risks, everyone make Risk could that filed we call will that events SEC I materially started, our on set Actual forward-looking Report SEC. expressed to and get in statements. filings as XX-Q remind results any or

update today call revise relied as In statements forward-looking made as on or any subsequent date. not upon any of forward-looking any should our addition, to views disclaim only this of obligation as representing any views statements. and be represent our specifically We

here Now, Jeff CEO, Albers. is our

Jeff Albers

XXXX good patients selective we to towards progress Throughout kinase made highly diseases. morning goal genomically our and transformative, the everyone. defined with Thanks, delivering Kristin, portfolio have across of excellent medicines

stromal or mastocytosis. marked by an in BLU-XXX GIST, culminate and productive additional in to quarter for systemic progress fourth this expect We in data disclosures tumors gastrointestinal extremely

years with to come. a advance to continued we the for growth and pipeline expand Importantly, to fuel also our potential research differentiated continue

to are into by commercial we we As haul company, principles. guided a core Blueprint Medicines integrated stage fully four work

First, continued rigorous science.

development. clinical rapid Second,

highlight will patients. growing focus portfolio on we today's and provide an momentum Third, update On an call our fourth, management, pipeline. continued unyielding and our on clinical disciplined research

by selective in presentation HCC updated want call hepatocellular several highlighted Our September. highly carcinoma clinical to of the inhibitor, that for BLU-XXX, is from in ESMO I takeaways presentation our are data to progress There at the key patients your with or attention. advanced FGFRX

new patients. the compelling BLU-XXX and data in in XX% pre-treated objective nearly for seen driven demonstrated with heavily HCC. First, FGFR radiographic activity clinical in of tumor responses the patients half of reductions patients With

HCC and pathway defined the as Second, biomarker data approach our in a a selection subset patients patients. of activation established FGFRX of disease supported driver

preliminary Third, group control prior TKI-naïve had the of the provided treatment an and received the Overall, exploration and who with disease in driven data immune checkpoint BLU-XXX of the supports HCC, further data encouraging both sorafenib. FGFRX evidence such population in prolonged in of TKI small combination with as patient not a patients inhibitor.

additional initiate over BLU-XXX pathways generate plan of for regulatory approval. the course we data As potential on interactions we with towards authorities XXXX, to

Turning to pipeline. our broader

data selective and year. progress from systemic and as to as well inhibitor. the our PDGFRα We plan make with updated BLU-XXX, to studies the important of GIST We highly report before potent continue advanced end ongoing in our mastocytosis KIT in

meeting for Oncology Annual will November Tissue first be The on Connective GIST disclosures the these at of Society XX. XXnd Friday,

the trial. clinical continued our portion enrollment of disclosure of ongoing presentation X last Phase We the an expansion to based update will expect ASCO from this incremental be on

mutations. harboring PDGFRα breakthrough we with DXXXV advanced BLU-XXX As FDA of disclosed for received June, designation treatment GIST, the in patients therapy

populations of of in line X half BLU-XXX BLU-XXX the the will progression broader support XXXX. addition, data on of initiate with versus clinical of setting global In ASCO, a are This to patients first we KIT-driven at regorafenib based free third on development shared Phase survival encouraging, track randomized in GIST. trial a in

For in data criteria, assess response most want any will with the comprises advanced the will mastocytosis we expansion based available. rigorous to IWG disclosure that the data have we safety systemic on we I data selective also response updated which importantly share include inhibitor, and approach systemic data update, to along may will early full highlight The RET escalation mastocytosis. our assessing BLU-XXX.

this Philadelphia. you the these shared show we BLU-XXX These know, activating multiple X including against BLU-XXX tumors. KIFXB, Molecular RET non-small is highly that mutations we medullary including RET of meeting As lung against lung mutations other Phase potent mutations. to Targets cell for initiated in in non-small Earlier year Last a and are drivers solid in or with may data cancer, BLU-XXX as at weekend fusions thyroid key gatekeeper and pre-clinical trial Triple cancer drivers predicted advanced cancers. resistant fusions cancer in data well as patients

the enrollment We continue are this we clinical first XXXX. of with and to investigators on initial to of be our the in data from pleased trial and half enthusiasm share program track

contributions has Murray Senior operational extensive strong from us In potential regulatory Finally, were Pharmaceuticals focus been team our for brigatinib. commercial the joins to where of manufacturing meet of to all clinical We a Medicines. supply Operations, as Technical he for as and to look always launch ponatinib team. develop and we oversaw future Chris for therapeutic building Dr. and our President activities we ARIAD his commercial strategic experience Chris and forward commercial Blueprint advanced plans needs. welcome management a key at late and to development, aspects us expand October, review including Vice and most clinical thrilled cohesive brings stage who investigational

to turn to depth. to Marion? Now our more Dorsch, Officer, in over portfolio call Scientific I like research discuss would our Marion the Chief

Marion Dorsch

to our strategy and therapeutic discussing before I our morning, providing on key Thanks, start Jeff, good some updates overall portfolio. discovery by want everyone. research

scientific a medicines. you enabled have develop highly pipeline take platform As to pride our and of capability we selective research in know, us great robust which kinase

a highly patient kinase disease. validated for kinome. nearly selective two and target of chemical built is over rapid Medicine. points Blueprint on kinase for therapeutic This our of inhibition that but foundation compounds We detailed is been capability. maximize develop that by abnormally to potential enables by selection, program proof from radar target library has our each us our continuously kinase track. team our at excited week, subset selective All starting the focuses candidate the has techniques following bypass human rare therapeutic selective chemical target. historically improved internally the identification highly candidates. pursue been screening this patients we compound us discovered off concept, the then an general, I that my of and of of our a was current and carefully to points is therapeutic has years in to company. discovery development compounds What identified the The to last potent providing discovery therapeutic target of scientists Furthermore, that research combined inefficient the candidates to were which library kinases enabled annotated of therapeutic expand to with for liability other opportunities cancer our limit When on approach several difficult decades approach analysis our first individual activated foundation with achieve starting defined to is of difficult libraries fully to or proprietary activity. of a therapeutic developed proven severe just distinguishes to have against for well and a that has evaluate importantly, am In designed traditional

enhance elicit that For or targetable the identify example, our collaboration immunokinases are Roche, have potential we under cancer. against with immune to working to response

potential the and Our to our scientists strong range unlock we talented development broad have technology combined platform highly have of to we a with responsibility motivated a recognize resources carefully. and deploy opportunities

our prioritization our to to program transform with with our portfolio management are research portfolio care. today. providing this and three committed approach, are patient the potential of the updates We important we Consistent of discipline creative on

are pleased progressiva to for extremely I continued FOP. fibrodysplasia research program or ossificans of prioritize First, advancement am our ALKX kinase targeting planning treatment of we the the that

a for the Beginning characterized connective of progressive abnormal of at FOP a medium pulmonary disorder ligaments scientific program the tissue before referred results age severe, this to early of by rare of of and a skeletal in The age activity. to XX disease. bone. into due FOP tendons Our leader childhood ultra abnormal is and loss as in experienced function, muscle, kinase catastrophic FOP restrictive is death gene, disability cause which mutation the a patients ten, ultimately disease. premature typically ALKX joint international transformation

treat the and to selectively Our ALKX candidate of disease. cause that research the inhibit program a underlying seeks identify therapeutic can

us to In to termination as program As portfolio you and collaboration on our the their certain of back a of core because transition program review areas. know, strategic into us therapeutic informed decision focus a to in the their resources enabled on program. portfolio which this effective wholly-owned exit October, decision following the Alexion complete July our

any of to obligations result the no a As termination, longer exclusivity have we Alexion.

have We obligation any or payment also don’t Alexion. to future current

We a evaluating well-designed with number move of candidate limited are currently identifying compounds therapeutic a goal the the into of clinic. to

productive want a seamless for the on and partnership over transition. last we support to Alexion thank Importantly, years two their

Second, program liver FLC, sub-type fibrolamellar for carcinoma adults. of rare typically the our a de-prioritize the or treatment we research cancer of plan to that targeting young effects kinase PRKACA

advance and our this research efficacy FLC lack have to learnings FLC. may We preliminary developments models encountered suitable challenges in the scientific of we program based to opportunities the share on to potential of the to consider our Here community field. further advancing due plan future with

kinase now research have our an an research kinase undisclosed three program we with undisclosed and target. have target program we wholly-owned program Combined additional Third, an in programs portfolio. nominated XXXX, another in nominated FOP research for wholly-owned for the

on initial biology two selective development. undisclosed target compounds Our identifying on will further for focus the the programs and work validating

sharing progress, more forward programs As we these to look information.

important portfolio recognize management. also partnerships disciplined We play in the role that

our expertise making progress and grateful remain are make the continue to the with contributions collaboration collaboration advancement cancer we the we with to on are and very for Roche's Roche. significant We of program. focus pleased immunotherapy We together

and R&D third will our efforts. our I quarter. financial will Mike partnership additional review the We over expansion turn that ongoing evaluate continue enable similarly from opportunities of call to to acceleration may the the results now to potential

Mike Landsittel

and Marion. Marion well maintain balance Medicines just development sheet outlined. are and positioned continues Jeff clinical the on and strong both Thanks, that pre-clinical we Blueprint activities execute to to a

third began million quarter revenue million Collaboration to was program under of the XXXX, as walking me we Let quarter primarily the Medicines. Alexion of increase to compared were start XXXX. recognized the in $X.X collaboration This you through back $X.X same transition due for Blueprint our by the the period P&L. for third to revenues FOP

receive General be or quarter longer entitled personnel the in just share Net third of to related milestone as R&D well $XX.X associated expenses. in a per period our G&A million Research $XX.X million not to with result of The will same XXXX, in in net were payments the as the a fees. the we million for loss increase for will last collaboration to the as for BLU-XXX, per year. million increased related as well pointed is manufacturing XXXX. $X.XX an spending increased expenses for to no compared out, Marion the our of Alexion, additional reimbursement million to $XX.X and share same $X.XX personal and As primarily and XXXX. increased administrative FOP were any $XX.X or of XXXX million related compared BLU-XXX, due period increase R&D certain the compared them for of to loss expenses discontinuation program. expenditures quarter same quarter ongoing period expenses BLU-XXX, attributable increased advancing professional development spending and as headcount, increase third in clinical for expenses clinical the was for trials $X.X to $X.X primarily was to with from for The and

early ongoing supply BLU-XXX as balance commercial our efforts in to sheet. build infrastructure investments as requirements to cash to in net compared cash to The operating with to and expand refine as was December our totaling capital and to the drug planned follow-on increase proceeds arm offering pre-commercial ended trial. expenses with activities Phase million XX, $XXX.X X are the quarter we and that XXXX. our the from due and existing last GIST, path of And fees trial milestone our clinical and cash support used continue option expanding enable turning Now of to equivalents half our $XXX.X regulatory primarily the includes payments our to include million, line ongoing the global operations. to quarter, BLU-XXX and clinical cash, We clinical our $XXX.X in cash collaboration discussed we by current excluding our equivalents for an we on ramping provide This April XXXX. plans, potential will in any investments to partially to and us of expect XXXX, TKI-naïve BLU-XXX under Based with of cash, expenditure Roche, second offset preparing that fund fund closed up our GIST, our I advanced additional activities. development manufacturing into third patients of to beginning million

our increase fully subsequent execute quarters continue to our We in operating the we integrated building will vision open expect to your continue a questions. biopharmaceutical With up that on now company. that would we like Operator? to expenses call for of as


[Operator question of line comes first our Instructions] Goldman Terence the And Sachs. from from Flynn

is open. now Your line

Terence Flynn

and there how us guys can if you to this think Maybe, just Jeff, versus the is path accelerated about in setting data, help a market you for the Midostaurin wondering about SM you indication. advanced to differentiating as potential think look out Thanks. XXX

Jeff Albers

Terence. Thanks,

on we data. answered year-end. still best data BLU-XXX both as our as actually mentioned, track we the advanced of regulatory of how as in share well at I we path, by are So in time part questions, for study that to differentiate both systemic terms share the mastocytosis think we And are from your

have time next going are what disclosed regulatory about won't we plans in of a steps. before, we terms talk that we will at be providing As update our forward but

Terence Flynn

the And Thanks. assess up for will cohort, for maybe Will one we the enough response. sounds dose IWG know the cohort? you follow expansion I will follow-up. it IWG response Thanks. have Okay. data to escalation but like we just get expansion

Jeff Albers


an correct. into I I would For not fit follow-up are should say of which the be portion portion, of necessary, be the Because patients that perhaps expectations share the data criteria that will is there all will time, you the one or sufficient there from IWG escalations the we IW be the can and response, patients the that expansion for we suppose the but the share study. in can two


next And Eric comes our you. Thank line of the Cowen Company. from and from question Schmidt

is line Your now open.

Eric Schmidt

the similar questioning what be Maybe hoping Jeff another say, But was the Congrats around progress. type are might follow-up and of expansions. The the I us have escalation each number correct? data in line on give of and/or of limited that we SM. you three set Andy. to little like are patients flavor you on either see and in patients sounds you the going all to it cohort you for of know bit three a I of terms across can going of if cohort and dose that duration those more expansions, could XXX is

Andy Boral

Eric, Andy. that. take I will It's

Jeff the escalation present part of about prefer year on we sufficient the will the off lot don’t present the the you the to. at But as I the refer IWG we plan it I to updated, of will the we as is there the to study details. data it criteria see detail information into ask activity reiterate, for will expansion get part of definitely response do So are end data and safety think including from of to the available what and soon for wait as and look a said we to on just guess like. focus presentation both you the and is and they to study. And But

Eric Schmidt

sense you. to we looking question What can see enrollment when forward inhibitor. Thank us another be going? Maybe RET you Okay. you of might data on Andy, give might and a the there? cohorts is up

Andy Boral


next we of in it's data this, to and as XXXX expect I accruing year. So first the do will say half anticipated share

results and meaningful been in to a dose activity. available of Our across has data after patients safety always enough Phase about X we and make range statements levels to have share preference potential

So, again, we you bit we when more a will have update say.


comes Thank you. Chico from And James. from question next Laura line the of Raymond our

Your is now open. line

Sarah Frank

Sarah Laura This for is Frank on Chico.

bit you a to talk demonstrate do in need you So and compelling you that the ALKX that’s efficacy. what further and you. with landscape the you the also program. about data competitive what think guys Thank Could have terms all you about seen little clinical how now are of in progressing

Jeff Albers

take talk of will have This Thanks, the I portion competitive I question will a Sarah. landscape. Jeff. and that Marion about bit first is the then

program. been program we other the Blueprint the as and wholly-owned smoothly how encouraged through really are now by went obviously, just evaluate we of collaboration have we the So, and unwinding Alexion position the just going process a in with that fact can any where that

terms seen provided In a update conference as we have do similar at or provide look to scientific program more move what have other to Blueprint programs we we to any forward. we is a a What date of historically. will updates the comprehensive stage not

giving So the feel time preliminary. competitive And more this detail landscape, maybe at Marion?

Marion Dorsch

disease such, discovery Yes. kinase I underlying FOP with I an activated to cause defined a abnormally genetically kinase mean Blueprint's is match in rare genetic just is a reiterate. as in diseases. strength whose and great

strategy candidate FOP. the cause believe role this selectively the ALKX we inhibition of in the And receptor of is the current the approaches to targets clinical plays ALKX that differentiation underlying an The retinoic Regeneron gamma be for kinase, bone agonist transformative to the is modulate given truly alternate and acid that of that kinase development develop to has [contracytes] many Our is a central disease, potential use mechanisms. will which antibody of the [ph] Clementia stage ligands against patients. one ALKX. in pursuing pursuing ALKX

our agents enough disease potential existing after to really has or approached differentiated the the and go feel trials the a trials. of we from in great that driver So is

Sarah Frank

at released ASH? I for one if will advanced confirm the Can more? Can you squeeze be BLU-XXX Okay. data SM

Jeff Albers

Jeff. is We This that. cannot confirm

of we will by data will the present this data, end share year. We


BTIG. of next our the from line comes Thank Dane Leone question you. And from

open. now Your line is

Dane Leone

I to versus understanding three what something in is a, trying people back kind I are out from Alexion I like evaluating it the And and messaging where From developing have understanding of think, on are it the we you it then currently sits. you get this is FOP, just that program So where your the committed know going correct progressing October, taking I here. today guess, very after market. to b, guess team. is sounds

I of think us just trying going pretty for are market boring, maybe more late a I efforts think then think do later large the from bit a understanding, infrastructure details few number about into you moving that just you a clinical you are you of one guys and expect it's us give should our disorder, we lot was lot I road. is? of if opportunity up. into about a a I of terms efforts. outlined, XXXX As how that’s manufacturing so of a FOP I you of in clinical to wondering programs that follow actually you in guess could have facets understand stage little And the are company and up place putting going you. ROI Thank some the from that a building talk down did but more rare wrapping what other commercial

Jeff Albers

So team this along is parts Jeff. I the it will and then other question three here. I parse members will take of different the to first the option into maybe and your pass

we has and and driver inhibitor, disease, confident program. notion of with in rare a to early program kinase Alexion at enthusiasm is the has certainly opportunity that enthusiastic been went along say, disease, would first about. So yes, and internal Blueprint we you identifying rare guess a as days I ALKX from of Medicines grown. program characterize selective genetic that could we a potent very highly question correctly. And enthusiasm This that that I because create that a your The increasingly portion for ALKX advanced our were a

there as along past calls are I stop the appropriate. part have the of Now preclinical within to other talked slow or risks our way job and often programs is program, on programs when that about team's

other what's this study, the that program we next stop that as with still program. Blueprint next to with any we are can hurdles about a experiment always there program think the do So those what's

opportunity But to had different. agreement you it's have the no moment, Maybe, is this at couple one think and months. place Alexion of fortunate the of we we last really the quite unique landscape want competitive this feel the to over unwinding Marion again? hit the So of a take

Marion Dorsch


we potential have cause underlying the mean compared approach I to many we in potential. have earlier, and is has And enough after the gamma pursuing Clementia targeting much disease we RA compared whose a compared Regeneron feel feel differentiated And that is of mentioned a the from disease I truly that to a going later little of As is other to mutated kinase our process. ALKX of to to agonist bit that the to transformative ours this ALKX. which different one approach similar enters in more after approach is the angle but it ligands approaches,

Jeff Albers

take And differentiated have disease, is will of the will on maybe transformative just I that Jeff, Yes. time regardless that have approach, the opportunity, think the if forward. opportunity impact a you add we to any we this have program the of we size a

the lead and sound our program we which positive is disease maybe, from on progress. about role programs, often talks those biologist And catastrophic differentiated the a a pursuing you other if have have think if is of impact to a those rationale programs ramping chemical have FOP matter complementary that’s take third got Mike, to up can opportunity whether this portion biological or we or a activities. we and a the As worth will question I

Mike Landsittel


gear with then as we supply. portfolio planning continue manufacturing the expect a we Just now as for we clinical think next supply are well, for also across part out to which Phase commercial not in just organization but increasingly X in third taking of And we for initiate the the GIST molecules line the build to clinical first year. to up I the advance, steps as are trial particularly, organization

commercial validation at initiation look to batches. starting So future stability batches of registration the and in

the infrastructure of lot what are planning then side, on assess to we phases are that of build. And we in And the like pre-commercial forward. the we so in the begin look of we kind kind is as organizations focusing as commercial move a where


Jefferies. And question Carmen line next our from of you. Thank Augustine comes the from

line is open. now Your

Carmen Augustine

there being data data on in views read program of kind through the a competitive to from I small you month. was So of was the some despite terms dataset XXX if program. this have curious of any a earlier RET cut it

Jeff Albers

This is us. saw Maybe initial Andy Jeff. question was take data, I will the think to ask the add to But, then we and not stab color. obviously, We surprising the at of to notion highly have to a developing The confer the selective and the a to patient what population. potent study RET is in similar done. ought approach benefit very inhibitor we patients, it

that’s we So announce amount in that have sufficient our right in to sharing through, for still you always we to terms sense when We or a read a of that we XX of think starting completing of It's and perspective from rationale why forward of the Medicines think wrong. way data and that’s define will plus trials [ph] is can appropriate in the it, the whether for safety year. we [partly] half next I that challenging patients, Blueprint always to so want efficacy. data look first get start

Carmen Augustine

then pursuing around into Do any have you indication Okay. for updated Thanks. BLU-XXX. another one. quick SM Thanks. thoughts And an just

Jeff Albers

that Sure. don’t why Andy, question? you take

Andy Boral


evaluating into an So SM pursuing SM we into or BLU-XXX. remain in earliest interested with an very

first profile. the as levels, improvements a As in reductions, bone and showed mast well and and as reductions year at tryptase good cell terms we are Really last two by both very the BLU-XXX. dose with evidence very safety marrow in of setting we the of clinical of ASH encouraged activity

in [indiscernible] And the of year we that those opens So we leads. over pursuing but been for the actively have disease BLU-XXX also have potentially really more we been, the door think the population. advanced very course both in developing

lives, us We particularly have endpoints get helps a continue ISM we from from mastocytosis a ways. patients' it's you of patients patient registry to Better important impact tests. regarding registry what think in about on impact lot data on symptoms because that from regulatory and about and of registry potentially all very and many lab really than get this

tool. like few working patient indolent with being something endpoint likely that outcome to will in a months collaborators reported up mastocytosis. that indolent develop study an systemic been We have over last the a mastocytosis think specific external primary in We end

actively patients. over helping plans And than are usually they the we us develop, been with have been we These A are more think that. typically study past XXX month information and group a care allergists different disease. the work. we these be bit when provide and we year, protocol have for SM to ISM. of developing So meeting dermatologists clinicians for our we certainly will good later in we will And advanced in update this pretty for we ongoing evaluating regarding a


JMP from our next line from you. of Thank And King Mike the question Securities. comes

line Your now open. is

Mike King

the first GIST? PDGFRα what is going to Most have for your line answered. of my you said patients with questions have been Jeff, I be may missed it, have but strategy

Jeff Albers

This is Jeff.

with path path patient communicated designation on registration of receiving potential based have our breakthrough back forward PDGFRα that on We and previously a that then the forward to coming was in agreement population. FDA

believe that at So at matures and Phase the line shared previously, front ASCO next we form registration in the most consistent data CTOS that upcoming X GIST. the in PDGFRα that basis with of have study, if what to there setting recently of we conference patients that the and week, arm expansion driven the a could way XX we expanded dataset, the our current

Mike King

population. am be KIT Okay. Correct? refractory I though the was CTOS I going to in relapse the misunderstood. sorry, I

Jeff Albers

one There a KIT the at single and then The that arms study. in and are matnib TKI. two other So it's the refractory arm PDGFRα phase. study, the requires recall least arm which

data we of the those share both will arms. update of that will So an be

started if study in we -- expansion limited March, into data the ASCO shared moved set. phase the data we a we that As you at recall, so of was time had

robust of both of of arms more will from study. that this data set phase expansion early be So a the

Mike King

Okay. then never, you the or light they we thought just any never out-licensing day on Great. will that And given see programs potentially to of other those will you programs de-prioritized. Have again?

Jeff Albers

Jeff. is This

will could opportunities at we time but look we therapeutic to third quite have certainly parties that and in think So to data look to narrow. is as make FLC our date we window collaborators in the we in with available that at this explore learning mentioned Marion the I particular

that a is learn think unless the partnership would learnings I unlikely. there those discussions collaborators in be we program So that opportunity, on that additional specific expands something with


from comes Instructions] And of [Operator next our from Canaccord. Arlinda Lee question line the

Your line now open. is

Arlinda Lee

couple. of might presenting a XX there was additional to And there ASH any have I are curious the AML. be indications, your XXX for that? I that On for respect plans additional some suggested subsets on with author if utility

Andy Boral

Arlinda, take it's I that one. Andy. will

as to our all initial a are broad, looking try we driven quickest registration do yes, or expression, often as what third And AML a AML those factor So, example. at pretty potentially activated activation potential that compounds, to even a of XXX search [indiscernible] pretty in called subset interesting quarter mutations core the we in about diseases broadly cases of other opportunity. a indications the beyond KIT that’s it's KIT, with we a PDGFRα by see are actually thorough KIT XX. think There is of is primary, with contain primary, expression. activated and binding I KIT AML

patients to in some we And are in to talking opportunities mastocytosis paths Similarly, so diseases. collaborators our we in of these see other PDGFRα about for particular folks who are think certainly looking forward.

on have there. we what any It any premature will be to specific give I specific plans. think would details be you we don’t doing

Arlinda Lee

to update providing And week will enrollment ASCO Okay. an XXX. you Have guess on up Great. mentioned you I maybe that? that you CTOS get were for expecting going follow Thanks. are in an of at mid-XX. completion the we update at be on next maybe but arm PDGFRα a then

Jeff Albers

This is Jeff.

and still update. the is are track that mid-'XX, guess we complete that So on in I to

at You update. will see that’s the more of it but CTOS

We on are still track.

Arlinda Lee

Okay. and room guess then guess, there of I about your [ph] are I and talking a strategic is history and housekeeping expeditious been And this a for doing later a am the it is have plans the in study were the question to is I collaborator that few expedite maybe natural more moving and on strategic maybe competitor a last curious players process. of little [KOLs] or given kind question. of I terms getting guys maybe of that then help you moving forward bit your what forward program. it's a committed guess to with being multiple

that. your Just for picture thoughts big curios on

Jeff Albers

So this is Jeff.

that think of detail is I premature. level

I if we hand to other or is a now right think become we as say, task the into program, and partner Blueprint the brings have move that to has the as ALKX wholly-owned possible. to we to at accelerate us program the for clinic suffice will program about any always that quickly as that like allow believe partnering And with see expand the molecules could expertise we think evaluate pre-clinically potential other development. any continue

Arlinda Lee

And new clinic of clarification. Okay. your maintaining the goal or one IND just for new still the you into a guys program into the Are one clinic year?

Jeff Albers


do time. we both is continue What or don’t I newly I way to continue way. in of programs to. Marion new in it invest since alluded know to some haven't pipeline say if it that we wholly-owned So that construct that our said I guess,

again year. year one So this one last and

Medicines. about just targets Perhaps nothing been of have program. as has There we up recent and so think robust in went we well with through to five most other discovery and notably collaboration, I working most than at the have, any slowed Blueprint we our as time collaboration time select that more and moment process the or are if this narrowed discovery the anything, in to contract efforts that targets. where is I this at novel efforts As Roche are the


Thank for remarks. you. at to Jeff the lines the closing over I this turn like to back Albers call questions phone am over would showing time. no And further I

Jeff Albers

Thank you, operator.

mastocytosis of questions about continues in away the one then the targets about pipeline I patient sharing call. all in statements be from is, systemic and to patients. by them There and that and BLU-XXX flow interesting defined opening in the came of GIST from Two, lives, subsets I So can we data grow think are will think to take that genomically identify an through would three update our things make specifically really research as, both year-end. from analysts. impact this

way from very of updates, And a answer that allows in that operate So till we heard. to we to a Medicines which we we strong is the those provide to appreciate in continue third, us some long or responsible, think accelerate questions term de-prioritize of work financially programs a is, a very Blueprint your that that development position and waiting we patience us to programs in allows on responsible manner.

and forward in soon. an providing and Blueprint time Bye, a bye. for I So the interest have day. with we you for thank all look great continued update story your Thanks again want to you very again to with that, and support your


Ladies and participation and disconnect. your gentlemen, may Everyone in for today's program the thank great concludes have This day. conference. a you now you